2633 (2633) Fair Value & Analysis

Healthcare · Market cap HK$2.1B

2 2633 2633 · HK

PriceHK$1.03

Fair ValueHK$2.73

Upside+165.0%

Quality55/100

Watch 2633 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$1.77 – HK$3.48

Fair value as of: Jul 2, 2026

From 25 valuation models · updated today

Share price −10.4% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$1.00 – HK$1.63 · fair‑value band HK$1.77 – HK$3.48 · the HK$1.03 price screens below the HK$2.73 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2633 (2633) currently trades at HK$1.03, while our model-based Fair Value estimate is HK$2.73 — implying the stock looks roughly 165.0% undervalued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 2633 generated revenue of HK$1.6B at a net margin of 19.2%. Revenue grew 4.7% year over year. It earns a return on equity of 12.5%. Net debt stands at HK$541M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.6B

Revenue growth (YoY) +4.7%

Net margin 19.2%

Return on equity 12.5%

Free cash flow HK$278M FY2025

P/E ratio 6.9

More key figures

Operating margin 25.4%

EPS (TTM) HK$0.1500

Dividend yield 8.7%

EPS growth (YoY) -1.2%

Net debt HK$541M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

2633 reported revenue of HK$1.6B in FY2026 versus HK$1.6B in FY2022, a compound −0.4%/yr. Reported net income was HK$302M in FY2026, compounding +14.1%/yr from FY2022.

Revenue −0.4%/yr

FY22 HK$1.6B

FY23 HK$1.8B

FY24 HK$1.5B

FY25 HK$1.6B

FY26 HK$1.6B

Net income +14.1%/yr

FY22 HK$178M

FY23 HK$251M

FY24 HK$267M

FY25 HK$301M

FY26 HK$302M

Is 2633 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.08	¥26.59	-44%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$26.19	R$26.01	-1%
Hansoh Pharmaceutical Group 3692	HK$29.30	HK$23.90	-18%
Divi's Laboratories Limited DIVISLAB	₹6,639	₹1,281	-81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2633 (2633) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$2.73 versus a price of HK$1.03 — about +165% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2633?

Our model-based fair value for 2633 is HK$2.73 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.03.

What is the quality score of 2633?

2633 has a Quality Score of 55/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2633 (2633)?

2633 reported trailing-twelve-month revenue of about HK$1.6B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2633?

The net profit margin of 2633 is about 19.2%, meaning it keeps roughly 19.2% of revenue as net income. Based on the latest reported figures.

Does 2633 pay a dividend?

2633 currently shows a dividend yield of about 8.65% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.